Vitamin D 3 (VD 3 ) analogues-containing ointments are known to occasionally cause hypercalcemia in psoriasis patients, and the frequency of hypercalcemia is suggested to vary based on the VD 3 analogue used. In this study, to address the differences in calcemic effects of VD 3 -containing ointments, the calcemic effects of marketed VD 3 -containing ointments, including calcipotriol (Cal), maxacalcitol (Max), tacalcitol (Tac), calcipotriol/betamethasone dipropionate (Cal/BDP) and maxacalcitol/betamethasone butyrate propionate (Max/BBP) ointments, were evaluated in a rat model of imiquimod-induced dermatitis. The topical application of Tac, Max and Max/ BBP ointments, but not Cal and Cal/BDP ointments, to the imiquimod-induced skin lesions significantly induced an increase in the serum calcium level compared with the vaseline-treated group. Calcemic effect of VD 3 analogues in rats treated with VD 3 -containing ointments was analyzed by evaluating the expression of vitamin D receptor target genes, such as Cyp24a1, Trpv5 and CalbindinD28k, in the intestine and kidney. Real-time reverse transcription PCR (RT-PCR) analysis showed that the renal and intestinal Cyp24a1 expressions in the Cal-and Cal/BDP-treated groups were significantly lower than those in the Tac-, Max-and Max/BBP-treated groups, suggesting that systemic exposure of VD 3 analogues in the Cal-and Cal/BDP-treated groups were lower than those in the other ointment-treated groups. In addition, the renal Trpv5 and CalbindinD28k expressions, calcium-transporting genes, were increased in the Max-and Max/BBP-treated groups compared with the Cal-and Cal/BDP-treated groups. Thus, because of the low systemic exposure of VD 3 analogues, Cal and Cal/BDP ointments have lower calcemic effect than the other VD 3 -containing ointments in rats with psoriasis-like dermatitis.
Introduction
The combination of the active vitamin D 3 [1, 1, 25(OH) 2 D 3 or VD 3 ] analogue calcipotriol (Cal) and the corticosteroid betamethasone dipropionate (BDP) is widely used to treat psoriasis. Corticosteroids are potent anti-inflammatory agents with broad immunosuppressive effects by blocking several inflammatory pathways and inducing apoptosis in leukocytes (Ashwell et al., 2000; Refojo et al., 2001; Rhen and Cidlowski, 2005) . VD 3 analogues promote the induction of keratinocyte differentiation, the inhibition of keratinocyte proliferation and the inhibition of cytokine production in T cells, dendritic cells and keratinocytes (Lovato et al., 2016) . Combination therapy of Cal and BDP (Cal/BDP) more strongly inhibited epidermal thickness and infiltration of T cells in psoriasis patient skin biopsy samples than Cal or BDP monotherapy (Fujiyama et al., 2016) . Thus, corticosteroids and VD 3 analogues synergistically improve psoriasis when their combination is applied to a plaque lesion (Fujiyama et al., 2016; Lovato et al., 2016) .
Topical agents containing VD 3 analogues are occasionally known to cause hypercalcemia in patients with psoriasis, and the frequency of hypercalcemia is suggested to vary based on which VD 3 analogue is used (Yamamoto et al., 2012) . Hosomi et al. (2016) reported that, compared to maxacalcitol (Max) ointment, Cal and Cal/BDP ointments have induced low calcemic effect because of low systemic exposure of Cal resulting from its low skin permeability and rapid hepatic clearance after topical application to normal rats. However, few reports are available on the mechanism underlying calcemic effect of VD 3 analogues in animals after topical application of VD 3 -containing ointments.
Active VD 3 orchestrates calcium homeostasis through the regulation of numerous target genes by binding to vitamin D receptor, a transcription factor of the nuclear receptor family. For example, active VD 3 upregulates transient receptor potential vanilloid type 5 (Trpv5) and Trpv6, which are epithelial calcium channels mediating calcium reabsorption at the apical surface of epithelial cells in the kidney and intestine, respectively (Van Goor et al., 2017) . VD 3 also induces CalbindinD28k, a calcium binding protein involved in the trans-cellular calcium transportation (Lambers et al., 2006) . In addition, 25-hydoxyvitamin D 24-hydorxylase (Cyp24a1), a catabolic enzyme that controls the intracellular levels of hormonal VD 3 , represents a particularly wellcharacterized vitamin D receptor target gene. The single administration of active VD 3 to mice induces renal and intestinal Cyp24a1 mRNA expression in a time-and dose-dependent manner, so it serves as a marker to predict systemic exposure of VD 3 (Meyer et al., 2007) .
In the present study, we investigated the effects of Cal/BDP ointment on the serum calcium level and the expression of vitamin D receptor target genes in the kidney and intestine of rats with imiquimod (IMQ)-induced psoriasis-like dermatitis to estimate the mechanism underlying its calcemic effect from the viewpoint of systemic exposure and calcium transport mechanism. In addition, psoriatic patients have an impaired skin barrier function and skin atrophy induced by topical corticosteroid treatment (Hengge et al., 2006; Takahashi et al., 2014; Vázquez-López and Marghoob, 2004) . Therefore, we also assessed the calcemic effect of Cal/BDP in rats with clobetasol-treated atrophied skin.
Materials and methods

Materials
Marketed ointments containing 0.64 mg/g of betamethasone dipropionate (BDP, SHIONOGI & Co., Ltd.), 50 μg/g of calcipotriol (Cal, LEO Laboratories Ltd.), 50 μg/g of Cal and 0.64 mg/g of BDP (Cal/BDP, LEO Laboratories Ltd.), 20 μg/g of tacalcitol (Tac, Teijin Pharma Ltd.), 25 μg/g of maxacalcitol (Max, Chugai Pharmaceutical Co., Ltd.), 25 μg/ g of Max and 0.5 mg/g of betamethasone butyrate propionate (Max/ BBP, Maruho Co., Ltd.) or 0.5 mg/g of clobetasol propionate (Glaxosmithkline PLC.) were used in this study. All of the reagents were commercially available.
Animals
Male Hairless Wistar Yagi (HWY)/Slc rats (5-6 weeks of age) were obtained from Japan SLC (Shizuoka, Japan). The rats were kept in a specific-pathogen-free animal facility with a maintained temperature of 19-25°C, humidity of 30-70% and 12-h day/night cycle and given access to food and water ad libitum. The experiments were conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, and the experimental protocol used in this study was approved by the Committee for Animal Experiments at Kyowa Hakko Kirin Co., Ltd. (Shizuoka, Japan).
Experimental protocol
HWY rats received a daily topical dose of 10 mg/ear or 25 mg/back skin of commercially available 5% imiquimod cream (IMQ, Beselna Cream; Mochida Pharmaceutical, Tokyo, Japan) for 4 consecutive days in order to induce psoriasis-like skin dermatitis.
To evaluate the pharmacological effects of BDP and Cal/BDP on IMQ-induced dermatitis and the serum calcium level, IMQ-applied ears were treated with Vaseline (Vas), BDP or Cal/BDP at doses of 10 mg/ear and 40 mg/ear 1 h after each IMQ application. During the treatment, the ear thickness and transepidermal water loss (TEWL) were measured using a dial thickness gauge (OZAKI MFG.) and vapometer (Keystone Scientific), respectively, before each IMQ application under isoflurane anesthesia. At 24 h after the final application of each ointment, approximately 3 ml of blood was collected from the abdominal vein of rats under isoflurane anesthesia for the measurement of the serum calcium level. After euthanasia, the right ear was stored in RNAlater (QIAGEN) until RNA extraction, and the left ear was fixed with 10% neutral buffered formalin for H&E staining.
To evaluate the calcemic effect of VD 3 -containing ointments, both ears of rats were treated with IMQ for 4 consecutive days and then treated once with Vas or VD 3 -containing ointments at a dose of 40 mg/ ear 24 h after the final IMQ application. Four h after the application of each VD 3 -containing ointment, approximately 3 ml of blood was collected from the abdominal vein of rats under isoflurane anesthesia. After euthanasia, the duodenum and kidney were obtained and stored in RNAlater (QIAGEN) until RNA extraction.
To induce skin atrophy, the ears of rats were treated with clobetasol ointment at 20 mg/ear 1 h after IMQ application for the first 3 days. Cal/BDP ointment was applied once to the ear 1 h after the forth application of IMQ. Four h after the application of Cal/BDP ointment, approximately 3 ml of blood was collected from the abdominal vein of rats under isoflurane anesthesia. After euthanasia, the duodenum and kidney were obtained and stored in RNAlater (QIAGEN) until RNA extraction.
Histopathological analyses
Samples from the ear and back skin were fixed in 10% neutral buffered formalin, embedded in paraffin, stained with hematoxylineosin (HE), and observed under a light microscope.
Real-time reverse transcription PCR (RT-PCR) analysis
RNA was obtained from the duodenum and kidney with an RNeasy Mini Kit (QIAGEN) and from the back skin with an RNeasy Fibrous Tissue Mini Kit (QIAGEN). Prior to the RNA isolation, all samples were homogenized with a TissueLyser (QIAGEN). Complementary DNA was synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). The expression of Gapdh, Cyp24a1, Trpv5, CalbindinD28k, IL-23p19, IL-17A, IL-22, IL-36α, IL-36γ, IFN-α, Keratin16, TNF-α, IL-6 and Cxcl1 was analyzed using real-time RT-PCR with Taqman Gene Expression Assay probes (Applied Biosystems) and TaqMan Gene Expression Master Mix (Applied Biosystems). RNA was quantified by comparing the threshold cycle number of each gene to the housekeeping gene Gapdh using the 2-ΔΔCT method.
Serum biochemistry
Serum was collected by centrifugation of blood in a BD Vacutainer ® SST™ (BD). The serum calcium level was measured by the ortho-cresolphthalein complexone (OCPC) method with an Automatic analyzer (7180; Hitachi High-Technologies).
Statistical analyses
Student's t-test or the Aspin-Welch test following the F test was used for the analysis of differences between two groups. Multiple comparisons among treatment groups were made using a one-way analysis of variance followed by Tukey's test or Dunnett's test, or the KruskalWallis test followed by the Steel-Dwass test or Steel test. In all tests, a P value of < 0.05 was considered to be statistically significant.
Results
IMQ-induced dermatitis in rats
First, to assess whether or not the topical application of IMQ induces psoriasis-like dermatitis in rats, IMQ was applied to the ear and back skin of rats for four consecutive days. The ear and back skin of rats displayed the three representative psoriasis-like symptoms of erythema, thickness and scaling after this four-day treatment with IMQ ( Fig. 1A) . A histopathological analysis showed that epidermal hyperplasia, hyperkeratosis and parakeratosis were observed on the ear and the back skin of rats after four-day treatment with IMQ, and pustules were observed, especially on the back skin of rats (Fig. 1B) . As shown in Fig. 2 , real-time RT-PCR analysis showed increases in IL-23p19, IL-22, IL-17A, K. Satake et al. European Journal of Pharmacology 826 (2018) 31-38 IL-36α, IL-36γ, IFN-α1, TNF, IL-6, Cxcl1 and Keratin16 after four-day treatment with IMQ.
Effects of Cal/BDP ointment on skin inflammation and the serum calcium level in a rat model of IMQ-induced psoriasis-like dermatitis
To determine the dose of Cal/BDP ointment that exerts a suppressive effect on IMQ-induced dermatitis in rats, rats were treated with Vas, BDP or Cal/BDP ointment at doses of 10 mg/ear and 40 mg/ear. The repeated application of IMQ to the ear of rats resulted in increases in the ear thickness and TEWL (Fig. 3A and B) . Compared with the Vastreated group, the increases in the ear thickness and TEWL induced by IMQ were inhibited in the BDP-and Cal/BDP ointments-treated groups. Cal/BDP ointment at 40 mg/ear significantly inhibited the ear thickening compared to the Vas-treated group (Fig. 3A) . Furthermore, Cal/ BDP ointment suppressed the increases in the ear thickness and TEWL more strongly than BDP ointment in IMQ-treated rats.
Next, the effect of Cal/BDP ointment at 40 mg/ear, which inhibited increases in ear thickness and TEWL, on the serum calcium level in IMQ-treated rats was evaluated. As shown in Fig. 3C , no elevation in the serum calcium level was observed in rats treated with Cal/BDP ointment compared with the Vas-treated group.
3.3. Effects of Cal/BDP ointment on the intestinal Cyp24a1 expression in a rat model of IMQ-induced psoriasis-like dermatitis Hosomi et al. (2016) reported that the serum concentration of Cal was below the lower limit of quantification during the first 48 h after topical treatment of both Cal and Cal/BDP ointments in normal rats. In order to estimate the systemic exposure of Cal, the expression change in Cyp24a1 mRNA, a vitamin D receptor target gene, in the intestine after the topical application of Cal/BDP ointment in rats with IMQ-induced dermatitis was evaluated. Rats with IMQ-induced dermatitis were treated once with Cal/BDP ointment, and the mRNA expression of Cyp24a1 in the intestine was analyzed by real-time RT-PCR. As shown in Fig. 4 , the intestinal Cyp24a1 mRNA expression was increased, with a peak at 4 h after the topical application of Cal/BDP ointment.
3.4. Effects of VD 3 -containing ointments on the serum calcium level and expression of vitamin D receptor target genes in the kidney and intestine of rats with IMQ-induced psoriasis-like dermatitis Next, to assess the calcemic activities of VD 3 -containing ointments, the serum calcium level and the expression of vitamin D receptor target genes in kidney and intestine were evaluated 4 h after the topical application of Cal/BDP, Cal, Tac, Max and Max/BBP ointments in rats with IMQ-induced psoriasis-like dermatitis. VD 3 -containing ointments were applied individually to psoriasis-like skin lesions induced by IMQ treatment.
Real-time RT-PCR showed that the renal and intestinal Cyp24a1 mRNA expression were significantly increased in all VD 3 -containing ointment-treated groups compared with Vas-treated group (Fig. 5A and  B) . In comparison among VD 3 -containing ointments, the renal and intestinal Cyp24a1 mRNA expression in the Tac-, Max-and Max/BBP ointments-treated groups were significantly higher than those in the Cal-and Cal/BDP ointments-treated groups ( Fig. 5A and B) , and the renal Cyp24a1 mRNA expression in the Max-and Max/BBP ointmentstreated groups were significantly higher than that in the Tac-treated group (Fig. 5B) .
In mice, VD 3 has been reported to induce the renal expression of several calcium-transporting genes, including Trpv5 and CalbindinD28k, which play an important role in calcium reabsorption in the kidney (Lambers et al., 2006) . As shown in Fig. 5C , Trpv5 expression in the kidney was significantly increased in all VD 3 -containing ointment-treated groups compared to the Vas-treated group (Fig. 5C) . On comparing the VD 3 -containing ointments, the Trpv5 expression in the Max-and Max/BBP ointments-treated groups was significantly higher than in the Cal-, Cal/BDP-and Tac ointments-treated groups. The renal CalbindinD28k mRNA expression in the Max-and Max/BBP ointments-treated groups was significantly higher than that in the Vastreated group (Fig. 5D ) and also significantly higher than those in the Cal-and Tac ointments-treated groups on comparing the VD 3 -containing ointments (Fig. 5D ).
As shown in Fig. 6 , compared to the Vas-treated group, a significant increase in the serum calcium level was observed in the Tac-, Max-and Max/BBP ointments-treated groups but not in the Cal-and Cal/BDP ointments-treated groups. On comparing the VD 3 -containing ointments, the serum calcium level in the Max/BBP ointment-treated group was significantly higher than that in the Cal-, Cal/BDP-and Tac ointmentstreated groups (Fig. 6) . The serum calcium level in the Max ointmenttreated group was also significantly higher than that in the Cal/BDP ointment-treated group (Fig. 6) .
Effects of Cal/BDP ointment on the intestinal Cyp24a1 mRNA expression and serum calcium level in rats with clobetasol-treated skin atrophy
Topical corticosteroids are widely used in psoriatic patients and are known to cause skin atrophy. Percutaneous absorption of topically applied drugs in corticosteroid-induced atrophied skin is reportedly increased compared to that in intact skin, resulting in enhanced systemic exposure to topically applied drugs (Meingassner et al., 2005) . Therefore, the effects of Cal/BDP ointment on the intestinal Cyp24a1 mRNA expression and serum calcium level in rats treated with IMQ and IMQ/corticosteroid were compared.
To mimic skin atrophy in psoriasis patients with corticosteroid treatment, IMQ-applied rats were treated with clobetasol ointment for three days. As shown in Table 1 , the ear thickness was significantly increased by IMQ treatment, but clobetasol treatment significantly reduced the ear thickness to below that of normal skin. To evaluate the systemic exposure to VD 3 analogues in Cal/BDP-treated rats, the mRNA expression of Cyp24a1 in the intestine was analyzed by real-time RT-PCR. The intestinal Cyp24a1 mRNA expression after Cal/BDP ointment application in rats with IMQ/clobetasol-treated skin was higher than that in rats with IMQ-treated skin (Fig. 7A) . However, there were no marked differences in the serum calcium level between the two groups (Fig. 7B) .
Discussion
Topical agents containing VD 3 analogues are occasionally known to cause hypercalcemia in patients with psoriasis. Hosomi et al. (2016) reported that the lower calcemic effect of Cal/BDP ointment than Max ointment is caused by the lower systemic exposure of Cal than Max in normal rats after topical application of ointments. However, the mechanism underlying calcemic effects of VD 3 -continging ointments remains to be fully elucidated. In this study, the effects of VD 3 -containing ointments on the expression levels of vitamin D receptor target genes in the kidney and intestine were evaluated to estimate the systemic exposure of VD 3 analogues and to understand the mechanism underlying calcemic effects of VD 3 -containing ointments in rats with IMQ-induced psoriasis-like dermatitis.
It has been reported that rats are likely to be a relevant species for the prediction of an acute calcemic response of VD 3 analogues in humans (Baroni et al., 2008) . However, no appropriate rat model with psoriasis-like skin dermatitis has been developed. Although it is well 
Table 1
Changes in the ear thickness in IMQ-and IMQ/clobetasol-treated rats. The ears of rats were treated with clobetasol ointment at 20 mg/ear or not treated with clobetasol ointment 1 h after IMQ application for 3 days. Twenty four h after the final treatment of clobetasol ointment, ear thickness was measured using a dial thickness gauge. Mean ± S.D. of 3 rats. a P < 0. et al., 2009) , there has been no report of an IMQ-induced dermatitis model in rats. This is the first report in which the topical application of IMQ to the ear and the back skin induced psoriasis-like dermatitis in rats phenotypically and histopathologically resembling human psoriasis and IMQ-induced dermatitis in mice. In addition, the upregulation of cytokines involved in the pathogenesis of psoriasis, including IL-23 and IL-17 (Lee et al., 2004; Li et al., 2004; Lowes et al., 2008) , was observed in IMQ-induced skin lesions in rats, suggesting that a rat model of IMQ-induced dermatitis also pathogenetically resembles human psoriasis. Cal/BDP ointment suppressed the increases in ear thickness and TEWL more potently than BDP ointment in IMQ-treated rats. This result is consistent with the clinical observation that combination therapy of Cal and BDP markedly improves psoriatic lesions compared to Cal or BDP monotherapy (Fujiyama et al., 2016) . Thus, a rat model of IMQ-induced psoriasis-like dermatitis is an appropriate model for testing combination therapies of VD 3 analogues and corticosteroids. Hosomi et al. (2016) reported that the serum concentration of Cal was below the lower limit of quantification during the first 48 h after topical treatment of both Cal and Cal/BDP ointments in normal rats. However, systemic administration of VD 3 induces the vitamin D receptor target gene Cyp24a1 mRNA in the intestine and kidney (Meyer et al., 2007) . In the present study, the intestinal Cyp24a1 mRNA expression was increased by the topical application of Cal/BDP ointment to the IMQ-induced inflamed skin, reaching a peak at 4 h after Cal/BDP ointment application. Monitoring the intestinal Cyp24a1 mRNA expression allow us to estimate the systemic exposure of VD 3 analogues after the topical application of VD 3 -containing ointment on IMQ-induced skin lesions.
In our comparison of VD 3 -containing ointments, the renal and intestinal Cyp24a1 mRNA expression of Tac-, Max-and Max/BBP ointments-treated groups was significantly higher than those in the Cal-and Cal/BDP ointments-treated groups, suggesting that the systemic exposure of VD 3 analogues in Cal/BDP and Cal ointments was lower than in other VD 3 -containing ointments. Furthermore, the serum calcium level in Cal/BDP ointment-treated animals was significantly lower than that in Max-, Max/BBP-and Tac ointment-treated animals (Fig. 6) . These results suggest that, in a rat model of psoriasis, systemic exposure of VD 3 analogues and calcemic effects of Cal and Cal/BDP ointments are lower than those of Tac, Max and Max/BBP ointments. Although some topical agents have been reported to show systemic effects due to unintended oral uptake in animal studies (Grine et al., 2016) , the oral ingestion of topical VD 3 -containing ointments may have little influence on the elevation of serum calcium level because the effects of Cal, Cal/ BDP and Max ointments on serum calcium level in this study is consistent with the results in the previous study using Finn Chamber discs to prevent oral ingestion (Hosomi et al., 2016) .
Trpv5 and CalbindinD28k are known to mediate the calcium reabsorption in the kidney (Hoenderop et al., 2002; Lambers et al., 2006) . We found that the expression of these proteins' mRNA was significantly higher in the Max-and Max/BBP ointments-treated groups than in the Cal-and Cal/BDP ointments-treated groups, suggesting that high systemic exposure of VD 3 analogues in Max and Max/BBP ointments increased the serum calcium level, possibly in part via Trpv5 and CalbindinD28k in the kidney. On the other hand, the serum calcium level, but not the Trpv5 and CalbindinD28k mRNA expression in the kidney, was significantly increased in the Tac ointment-treated group compared to Vas-treated group, suggesting that Tac ointment may induce a calcemic effect via a mechanism different from Max and Max/ BBP ointments. In general, bone as well as the intestine and kidney is an important organ for the regulation of calcium homeostasis by VD 3 . Tac ointment may modulate the serum calcium level by regulating the vitamin D receptor target genes in bone, but further studies are needed. The intestinal Cyp24a1 mRNA expression after Cal/BDP ointment application in rats with clobetasol-treated skin atrophy was higher than that in rats with IMQ-induced dermatitis, suggesting that the systemic exposure to VD 3 analogues is higher in rats with corticosteroid-induced skin atrophy than in rats with psoriasis-like dermatitis after topical application of VD 3 -containing ointments. This finding is in line with the report that the permeation of pimecrolimus was higher in clobetasoltreated skin than in vehicle-treated skin (Meingassner et al., 2005) . However, no marked differences in the serum calcium level after Cal/ BDP ointment application were noted between rats with clobetasoltreated skin atrophy and rats with IMQ-induced psoriasis-like dermatitis. Further studies are needed to clarify the precise mechanisms underlying low calcemic effect of Cal/BDP in rat with corticosteroidtreated skin atrophy.
In conclusion, Cal/BDP ointment as well as Cal ointment carry a lower risk of calcemic effect than other VD 3 -containing ointments because of their low systemic exposure of VD 3 analogues in rats with IMQinduced psoriasis-like dermatitis and in rats with corticosteroid-treated atrophied skin.
